Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Precision-driven recruitment that accelerates clinical trial success

Discover how hVIVO's recruitment division sets the gold standard in clinical trials, delivering efficient, tailored participant sourcing for diverse studies...

Oxford Nanopore unveils tech and pipeline updates at London Calling 2025

Oxford Nanopore Technologies recently unveiled innovative updates at its London Calling conference, showcasing advancements in nanopore sequencing technology and its applications...

Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF...

Poolbeg Pharma raises £4.7m through Placing and Subscription

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs...

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...

Poolbeg Pharma launches £4.1m fundraising

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs...

Cizzle Biotechnology raises £150k to support cancer test rollout

Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe...

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy...

Poolbeg Pharma targets severe flu and cytokine storms

Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy...

GSK Plc receives Japan approval for Blenrep combinations in multiple myeloma

GSK's Blenrep combinations gain approval in Japan for relapsed multiple myeloma, offering promising treatment options backed by successful clinical trial results...

Nuformix to present NXP002 data at ATS 2025

Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...

One Health Group unlocks new potential in spinal treatment

Experience relief from back pain with One Health Group, a leader in spinal care. Their expert team offers personalised, advanced treatments for improved mobility and quality of life...

Aptamer secures repeat contracts and new licensing deals

Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases...

GSK Plc to acquire Efimosfermin for $2 billion, targeting steatotic liver disease

GSK is set to acquire Boston Pharmaceuticals' promising liver disease treatment, efimosfermin alfa, enhancing its hepatology pipeline and addressing critical patient needs...

hVIVO proves it can deliver big on high-volume vaccine trials

hVIVO has showcased its excellence in clinical research by successfully executing a large-scale flu vaccine trial, demonstrating agility and operational expertise under tight deadlines...

POLB 001 targets deadly cytokine storms in cancer therapy

Cytokine Release Syndrome (CRS) complicates cancer immunotherapy, but Poolbeg Pharma’s POLB 001 offers a groundbreaking oral solution to enhance patient outcomes...

hVIVO publishes 2024 report and announces Board changes

hVIVO plc announces the release of its 2024 Annual Report and upcoming AGM, along with notable board changes, including the departure of key directors...

Unlocking the potential of clinical trials at FluCamp

Investing in clinical research with FluCamp means supporting innovative healthcare solutions while ensuring participant welfare through unique trial methodologies...

AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC

AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...
Search

Funds

Health

Precision-driven recruitment that accelerates clinical trial success

Discover how hVIVO's recruitment division sets the gold standard in clinical trials, delivering efficient, tailored participant sourcing for diverse studies...

Oxford Nanopore unveils tech and pipeline updates at London Calling 2025

Oxford Nanopore Technologies recently unveiled innovative updates at its London Calling conference, showcasing advancements in nanopore sequencing technology and its applications...

Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF...

Poolbeg Pharma raises £4.7m through Placing and Subscription

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs...

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...

Poolbeg Pharma launches £4.1m fundraising

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs...

Cizzle Biotechnology raises £150k to support cancer test rollout

Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe...

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy...

Poolbeg Pharma targets severe flu and cytokine storms

Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy...

GSK Plc receives Japan approval for Blenrep combinations in multiple myeloma

GSK's Blenrep combinations gain approval in Japan for relapsed multiple myeloma, offering promising treatment options backed by successful clinical trial results...

Nuformix to present NXP002 data at ATS 2025

Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...

One Health Group unlocks new potential in spinal treatment

Experience relief from back pain with One Health Group, a leader in spinal care. Their expert team offers personalised, advanced treatments for improved mobility and quality of life...

Aptamer secures repeat contracts and new licensing deals

Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases...

GSK Plc to acquire Efimosfermin for $2 billion, targeting steatotic liver disease

GSK is set to acquire Boston Pharmaceuticals' promising liver disease treatment, efimosfermin alfa, enhancing its hepatology pipeline and addressing critical patient needs...

hVIVO proves it can deliver big on high-volume vaccine trials

hVIVO has showcased its excellence in clinical research by successfully executing a large-scale flu vaccine trial, demonstrating agility and operational expertise under tight deadlines...

POLB 001 targets deadly cytokine storms in cancer therapy

Cytokine Release Syndrome (CRS) complicates cancer immunotherapy, but Poolbeg Pharma’s POLB 001 offers a groundbreaking oral solution to enhance patient outcomes...

hVIVO publishes 2024 report and announces Board changes

hVIVO plc announces the release of its 2024 Annual Report and upcoming AGM, along with notable board changes, including the departure of key directors...

Unlocking the potential of clinical trials at FluCamp

Investing in clinical research with FluCamp means supporting innovative healthcare solutions while ensuring participant welfare through unique trial methodologies...

AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC

AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...
Search

Funds

Health

FTSE 100

Funds